pite the high unmet need for the treatment of RSV, there is a dearth of emerging treatments in the clinic. Alnylam and Cubist were collaborating on ALN-RSV, but further development has slowed since Cubist opted-out of the collaboration after a mixed result in a phase 2 study. Alios (private) has an ora